{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Health&Fitness", "lead_paragraph": "Taking aspirin every day may lower the risk for prostate enlargement, a new study has found. Other nonsteroidal anti-inflammatory drugs, or Nsaids, like naproxen (Aleve) or ibuprofen (Advil or Motrin), have the same effect. ''At least half the patients I see are taking a daily aspirin for other health reasons,'' said Dr. Michael M. Lieber, an author of the study and a Mayo Clinic urologist. ''So this is a possible fringe benefit.''", "headline": {"main": "A Daily Aspirin May Decrease Prostate Risks", "kicker": "VITAL SIGNS: PREVENTION"}, "abstract": "Dr Michael M Lieber, Mayo Clinic urologist, leads study that finds men who take nonsteroidal anti-inflammatories like aspirin, ibuprofen or naproxen reduce their risk of enlarged prostate and elevated level of PSA, prostate-specific antigen; PSA proteins are used to test for prostate cancer; research is published online in American Journal of Epidemiology (M)", "print_page": "6", "word_count": 224, "_id": "4fd2afb98eb7c8105d89f205", "snippet": "Taking aspirin every day may lower the risk for prostate enlargement, a new study has found. Other nonsteroidal anti-inflammatory drugs, or Nsaids, like naproxen (Aleve) or ibuprofen (Advil or Motrin), have the same effect.      ''At least half the...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9502E5DF1631F936A3575AC0A9609C8B63", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "LIEBER, MICHAEL M"}, {"name": "organizations", "value": "AMERICAN JOURNAL OF EPIDEMIOLOGY"}, {"name": "organizations", "value": "MAYO CLINIC"}, {"name": "subject", "value": "MEN"}, {"name": "subject", "value": "PROSTATE GLAND"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CANCER"}, {"name": "subject", "value": "ASPIRIN"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "PSA (PROSTATE-SPECIFIC ANTIGEN)"}, {"name": "subject", "value": "NAPROXEN (DRUG)"}, {"name": "subject", "value": "IBUPROFEN (DRUG)"}, {"name": "subject", "value": "COMPUTERS AND THE INTERNET"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Nicholas", "rank": 1, "lastname": "Bakalar"}], "original": "By Nicholas Bakalar"}, "document_type": "article", "pub_date": "2006-09-05T00:00:00Z", "section_name": "Technology; Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Health&Fitness", "lead_paragraph": "A significant number of deaths and serious side effects could result from a mass smallpox vaccination program, according to a newly published analysis of historical data, and the exact numbers might depend on the strain of virus used to make the vaccine. The smallpox vaccine is a pure preparation of live vaccinia virus, a germ similar to cowpox and smallpox, and there are several different types. The United States stockpiles a strain called New York City Board of Health, or N.Y.C.B.H., while most European countries have stocks of the Lister strain.", "headline": {"main": "Risks of Smallpox Vaccine Vary by Virus Used as Base"}, "abstract": "Mirjam Kretzschmar leads study on smallpox vaccines that shows New York City Board of Health strain, which is used across United States, is less deadly than Lister strain of vaccine used in Europe; Centers for Disease Control and Prevention reports that federal government has enough vaccine for every person in US; recent research is published online in journal PLoS Medicine (M)", "print_page": "7", "word_count": 646, "_id": "4fd256218eb7c8105d7ff866", "snippet": "A significant number of deaths and serious side effects could result from a mass smallpox vaccination program, according to a newly published analysis of historical data, and the exact numbers might depend on the strain of virus used to make the...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=940CE6DF1631F936A3575AC0A9609C8B63", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "KRETZSCHMAR, MIRJAM"}, {"name": "glocations", "value": "NEW YORK CITY"}, {"name": "glocations", "value": "EUROPE"}, {"name": "organizations", "value": "BOARD OF HEALTH"}, {"name": "organizations", "value": "PLOS MEDICINE"}, {"name": "organizations", "value": "CENTERS FOR DISEASE CONTROL AND PREVENTION"}, {"name": "subject", "value": "VACCINATION AND IMMUNIZATION"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "SMALLPOX"}, {"name": "subject", "value": "COMPUTERS AND THE INTERNET"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Nicholas", "rank": 1, "lastname": "BAKALAR"}], "original": "By NICHOLAS BAKALAR"}, "document_type": "article", "pub_date": "2006-09-05T00:00:00Z", "section_name": "Technology; Health"}], "meta": {"hits": 2, "offset": 0, "time": 58}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}